Last update Jan. 15, 2021



Safe substance and/or breastfeeding is the best option.

Sulfonylurea that stimulates endogenous insulin secretion. May cause hypoglycemia.
Indicated in the treatment of type 2 diabetes.
Oral administration in one to three doses daily.

It is excreted in breast milk in clinically insignificant amounts (Moiel 1967).

Experts authors consider the use of this medication to be safe during breastfeeding (Serrano 2015).
American Academy of Pediatrics: medication usually compatible with breastfeeding (AAP 2001).

Diet, exercise, and breastfeeding improve blood sugar levels.

See below the information of this related product:

  • Maternal Diabetes mellitus (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)


  • Acarbose (Safe substance and/or breastfeeding is the best option.)
  • Glibenclamide (Safe substance and/or breastfeeding is the best option.)
  • Hypocaloric Diet (Safe substance and/or breastfeeding is the best option.)
  • Insulin (Safe substance and/or breastfeeding is the best option.)
  • Maternal Sport (Safe substance and/or breastfeeding is the best option.)
  • Metformin Hydrochloride (Safe substance and/or breastfeeding is the best option.)
  • Miglitol (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Toglibutamide is also known as Tolbutamide.

Toglibutamide in other languages or writings:


Main tradenames from several countries containing Toglibutamide in its composition:


Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 270 daltons
Protein Binding 95 %
VD 0.1 l/Kg
pKa 4.3 -
Tmax 3 - 5 hours
4.5 - 6.5 hours
M/P ratio 0.4 -
Theoretical Dose 0.00045 - 0.0027 mg/Kg/d
Relative Dose 0.004% - 0.02% %


  1. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract
  2. Mylan Ph. Tolbutamide. Drug Summary. 2009 Full text (in our servers)
  3. Nice FJ, De Eugenio D, Dimino TA, Freeny IC, Rovnack MB, Gromelski JS. Medications and Breast-Feeding: A Guide for Pharmacists, Pharmacy Technicians, and Other Healthcare Professionals. Part I. J Pharm Technol 2004;20:17-27. doi: 10.1177/875512250402000106.
  4. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  5. Moiel RH, Ryan JR. Tolbutamide orinase in human breast milk. Clin Pediatr (Phila). 1967 Aug;6(8):480. No abstract available. Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM